Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Apr 02, 2021 4:35pm EDT
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Mar 14, 2021 4:00pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Mar 05, 2021 4:01pm EST
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress Mar 01, 2021 4:05pm EST
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021 Feb 18, 2021 4:01pm EST
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Feb 08, 2021 9:00am EST
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Jan 19, 2021 4:14pm EST
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference Jan 10, 2021 4:06pm EST
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Jan 06, 2021 8:30am EST
